SBIR/STTR Research Award
SBIR TOPIC 107 REAGENTS FOR IMMUNOLOGIC ANALYSIS OF NON- MAMMALIAN AND UNDERREPRESENTED MAMMALIAN MODELS
Award amount
$596,519Program and phase
SBIR · Phase IAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- AMPERSAND BIOSCIENCES LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- HLWQXLFM7JR8
- Solicitation number
- PHS-2022-1
- Topic code
- 107
Research abstract
The hamster is a well-established model for several infectious diseases including influenza and SARS-CoV-2. Lack of hamster reagents has hampered pre-clinical studies of viral pathogenesis, host immunity, and vaccine development. The objectives of this proposal are to produce and test monoclonal antibodies against 10 cytokines and chemokines and 4 T cell surface markers for characterizing cytokine responses and examining T cells activation in the hamster models of respiratory infections. Completion of this project will provide high-affinity monoclonal antibodies that allow investigators to distinguish innate and adaptive inflammatory cytokine and chemokine responses as well as activated T cells, memory T cells, tissue resident memory T cells, and regulatory T cells in the hamster models of infectious diseases.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- DEVELOPMENT OF MONOCLONAL ANTIBODIES TO CHEMOKINES IN THE FERRET MODEL OF RESPIRATORY DISEASE.
- FURTHER CHARACTERIZATION AND VALIDATION OF MONOCLONAL ANTIBODIES TO STUDY RESPIRATORY
- DEVELOPMENT OF FERRET REAGENTS FOR USE IN THE CHARACTERIZATION OF IMMUNE RESPONSES TO RESPIRATORY INFECTIONS IN THE FERRET MODEL.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Safe-OPTION: Optical Physiology To Interrogate Oligonucleotide Neurotoxicity
- A Digital Biomarker for ALS - Pison Neural Biosensor
- Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI)
- Development of a novel oral brain penetrant therapeutic for ALS disease
- Engineering a Middle Meningeal Artery Embolization Model with Hydrophilicity and Hydraulic Resistance
Research funding history
4 SBIR/STTR records share this UEI (2020–2025). Reported award amounts total $2,854,147. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services